Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk
Under the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023
Denmark’s Novo Nordisk has settled a U.S. patent litigation case with Teva Pharmaceutical Industries Ltd. for its brand drug Victoza, Novo Nordisk announced last week. Teva first filed an application for a generic version of the drug with the U.S. Food and Drug Administration in early 2017.
Under the settlement agreement, Teva will be able to sell a generic version of the drug, which is used to stabilize blood sugar and reduce cardiovascular risk in type 2 diabetics, as of December 2023.
Teva. Photo: Bloomberg